What is the official website of MSD Magyarország ?

The official website of MSD Magyarország is http://www.msd.hu.

What is MSD Magyarország's cybersecurity risk score?

MSD Magyarország has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has MSD Magyarország experienced?

According to Rankiteo, MSD Magyarország currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has MSD Magyarország been affected by any supply chain cyber incidents ?

According to Rankiteo, MSD Magyarország has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does MSD Magyarország have SOC 2 Type 1 certification ?

According to Rankiteo, MSD Magyarország is not certified under SOC 2 Type 1.

Does MSD Magyarország have SOC 2 Type 2 certification ?

According to Rankiteo, MSD Magyarország does not hold a SOC 2 Type 2 certification.

Does MSD Magyarország comply with GDPR ?

According to Rankiteo, MSD Magyarország is not listed as GDPR compliant.

Does MSD Magyarország have PCI DSS certification ?

According to Rankiteo, MSD Magyarország does not currently maintain PCI DSS compliance.

Does MSD Magyarország comply with HIPAA ?

According to Rankiteo, MSD Magyarország is not compliant with HIPAA regulations.

Does MSD Magyarország have ISO 27001 certification ?

According to Rankiteo,MSD Magyarország is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does MSD Magyarország operate in ?

MSD Magyarország operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does MSD Magyarország have ?

MSD Magyarország employs approximately 53 people worldwide.

Does MSD Magyarország own any subsidiaries ?

MSD Magyarország presently has no subsidiaries across any sectors.

How many LinkedIn followers does MSD Magyarország have ?

MSD Magyarország's official LinkedIn profile has approximately 1,909 followers.

What is the NAICS classification code for MSD Magyarország ?

MSD Magyarország is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does MSD Magyarország have a Crunchbase profile ?

No, MSD Magyarország does not have a profile on Crunchbase.

Does MSD Magyarország have a LinkedIn profile ?

Yes, MSD Magyarország maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/msd-magyarorszag.

How many cybersecurity incidents has MSD Magyarország experienced ?

As of June 20, 2026, Rankiteo reports that MSD Magyarország has experienced 1 cybersecurity incidents.

How many peer or competitor companies does MSD Magyarország have ?

MSD Magyarország has an estimated 5,693 peer or competitor companies worldwide.

What types of cybersecurity incidents has MSD Magyarország faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

MSD Magyarország

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

MSD Magyarország Vendor Cyber Rating & Cyber Score

msd.hu

Add Your Compliance Badge

Az MSD a világ egyik vezető innovatív gyógyszeripari vállalataként több mint 130 éve végez fejlesztéseket az élet szolgálatában: a világ legnagyobb kihívást jelentő betegségei ellen fejleszt gyógyszereket és vakcinákat, hogy megmentse és élhetőbbé tegye a betegek életét. Az MSD a Merck & Co., Inc. USA-n és Kanadán kívül használt kereskedelmi neve, központja az Egyesült Államokban, a New Jersey állambeli Rahwayben található; Magyarországon három évtizede van jelen. Átfogó programjai és partnerkapcsolatai segítségével elkötelezetten küzd azért, hogy az egészségügyi szolgáltatások minél több ember életét segítsék. Az MSD élen jár az embereket és állatokat fenyegető betegségek, beleértve a rák, a fertőzéses megbetegedések – mint a HIV és az

MSD Magyarország A.I CyberSecurity Scoring

Scoring History

MSD Magyarország

MSD Magyarország CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

MSD Magyarország

Breach

9/2025

MSD060270611182...

Loading…

A.I.

MSD Magyarország Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for MSD Magyarország

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MSD Magyarország in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for MSD Magyarország in 2026.

Incident Types MSD Magyarország vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MSD Magyarország in 2026.

Incident History - MSD Magyarország (X = Date, Y = Severity)

Loading…

SUBSIDIARY

MSD Magyarország Subsidiaries

MSD Magyarország

Pharmaceutical Manufacturing

Website: http://www.msd.hu

Company Size: 51-200 employees

MSDPharmaceutical Manufacturing

MSD Saúde AnimalVeterinary Services

MSD LATAMPharmaceutical Manufacturing

MSD Animal HealthPharmaceutical Manufacturing

MSD EgyptPharmaceutical Manufacturing

MSD EspañaPharmaceutical Manufacturing

MSD FrancePharmaceutical Manufacturing

MSD DeutschlandPharmaceutical Manufacturing

MSD NetherlandsPharmaceutical Manufacturing

MSD GCCPharmaceutical Manufacturing

MSD ItaliaPharmaceutical Manufacturing

MSD SwitzerlandPharmaceutical Manufacturing

MSD TürkiyePharmaceutical Manufacturing

MSD PortugalPharmaceutical Manufacturing

MSD Animal Health Technology LabsTechnology, Information and Internet

MSD Australia & New ZealandPharmaceutical Manufacturing

MSD in the UKPharmaceutical Manufacturing

MSD South AfricaPharmaceutical Manufacturing

MSD BelgiumPharmaceutical Manufacturing

MSD Czech RepublicPharmaceutical Manufacturing

MSD JordanPharmaceutical Manufacturing

MSD PolskaPharmaceutical Manufacturing

MSD GreecePharmaceutical Manufacturing

MSD Animal Health UK LtdPharmaceutical Manufacturing

MSD LebanonPharmaceutical Manufacturing

MSD RomaniaPharmaceutical Manufacturing

MSD SverigePharmaceutical Manufacturing

MSD DanmarkPharmaceutical Manufacturing

MSD NorgePharmaceutical Manufacturing

MSD FinlandPharmaceutical Manufacturing

MSD SlovenskoPharmaceutical Manufacturing

MSD SRBIJAPharmaceutical Manufacturing

MSD ÖsterreichPharmaceutical Manufacturing

MSD UkrainePharmaceutical Manufacturing

Loading…

MSD Magyarország Similar Companies

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

Novartis

cb novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Loading…

NEWS

MSD Magyarország CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-56082

SUMMARY

Capgo (Cap-go/capgo) before 12.128.2 contains an improper access control vulnerability in the SECURITY DEFINER PostgREST RPC function public.record_build_time, which is granted to the anon role and callable with only the public Supabase publishable (sb_publishable_*) anon key. An unauthenticated attacker can insert rows into public.build_logs for arbitrary organizations and, because the function uses ON CONFLICT (build_id, org_id) DO UPDATE, can overwrite existing usage/billing records by reusing the same build_id for a target org. This enables cross-tenant tampering of billing build logs and financial-impact denial of service by inflating billable build time.

Published

Date2026-06-19

Updated

Date2026-06-19

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:H/A:N

cvss4

Base Score: 8.7

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-56081

SUMMARY

Cap-go before 12.128.2 contains an authentication logic flaw that lets an attacker register and control an account bound to a victim's email address before that email is verified. By enabling two-factor authentication on the pre-registered account, the attacker gains control over the account claimed under the victim's identity, allowing them to read and modify its state and enforce organization-level policies, while the legitimate user is denied access to the account tied to their own email.

Published

Date2026-06-19

Updated

Date2026-06-19

RISK INFORMATION (Score: 9.1)

cvss3

Base Score: 9.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:N

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.2

Exploitability

3.9

REFERENCES

CVE-2026-56080

SUMMARY

Capgo before 12.128.2 contains a flaw in the Enforce Password Policy feature: after a Super Admin enables the policy and successfully changes their password to a compliant one, the backend does not update the password-compliance state. As a result, the backend continues to treat the account as non-compliant and repeatedly forces password-reset prompts, permanently locking the Super Admin out of organization access (organization lockout / denial of service) despite valid authentication.

Published

Date2026-06-19

Updated

Date2026-06-19

RISK INFORMATION (Score: 4.9)

cvss3

Base Score: 4.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:N/I:N/A:H

cvss4

Base Score: 6.9

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:H/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

1.2

REFERENCES

CVE-2026-56079

SUMMARY

Capgo before 12.128.2 contains a cross-tenant authorization bypass vulnerability in PostgREST endpoints that allows org-scoped read API keys to access other tenants' webhook secrets and delivery logs. Attackers can query the webhooks and webhook_deliveries endpoints to exfiltrate HMAC signing secrets and delivery payloads, enabling forged webhook events against victim organizations.

Published

Date2026-06-19

Updated

Date2026-06-19

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

cvss4

Base Score: 7.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.6

Exploitability

2.8

REFERENCES

CVE-2026-56073

SUMMARY

Cap-go before 12.128.2 contains an authentication bypass vulnerability in OTP verification that allows attackers to bypass email verification by modifying server responses. Attackers can intercept OTP verification requests and manipulate HTTP responses to falsely mark verification successful, enabling unauthorized 2FA enablement and account takeover.

Published

Date2026-06-19

Updated

Date2026-06-19

RISK INFORMATION (Score: 9.4)

cvss3

Base Score: 9.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:L

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.5

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…